Drug intelligence / Profile preview

CLR4001

Development stage: Phase 2
Lead developer: Cleara Biotech
Modality: Small Molecules

Overview

CLR4001 is a small molecule drug developed by Clera Inc. as a modulator of dopamine receptors (DRDs modulators). Its mechanism of action involves increasing the sensitivity of dopamine receptors, aiming to reduce symptoms associated with Parkinson's disease. The drug was investigated for use in nervous system diseases and endocrinology and metabolic diseases, with its primary clinical development focused on Parkinson's disease. Development has been discontinued after reaching Phase 2 trials[1][3][4][6].

Other names: CLR-4001CLR4001CLR 4001CJH1CJH-1CJH 1

Targets

DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on CLR4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLR4001.

Explore the full profile